Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.
Novartis to expand its human vaccines presence in China
- Details
- Category: Novartis
Novartis has reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry leader in this country and expand the Group's limited presence in this fast-growing market segment.
New Merck Begins Operations
- Details
- Category: Merck
Merck & Co., Inc. (NYSE: MRK) outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation. The new Merck is a global health care leader aimed at providing innovative, distinctive products and services that save and improve lives, while satisfying customer needs and creating long term shareholder value.
World's largest malaria vaccine trial now underway in seven African countries
- Details
- Category: GlaxoSmithKline
A pivotal efficacy trial of RTS,S, the world's most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The trial, which is expected to involve up to 16,000 children, is on schedule, with more than 5,000 children already enrolled, researchers announced Tuesday at the 5th Multilateral Initiative on Malaria Pan-African Malaria Conference.
Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China
- Details
- Category: Novartis
Novartis announced a USD 1 billion investment over the next five years, increasing R&D activities in China and confirming Novartis' long term commitment to China's further economic development, health reform and improving the health care of the Chinese people. The Novartis investment will include a significant expansion of The Novartis Institute of BioMedical Research (CNIBR) in Shanghai.
Pfizer and Medivation Initiate Two Phase 3 Trials of Dimebon
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer's disease (AD).
Abbott Completes Acquisition of Evalve, Inc.
- Details
- Category: Abbott
Abbott (NYSE: ABT) has completed its acquisition of Evalve, Inc., the global leader in the development of devices for minimally invasive repair of mitral valves. The acquisition provides Abbott with a leading presence in the growing area of non-surgical treatment for structural heart disease.
More Pharma News ...
- Sanofi-aventis delivers a solid performance in third quarter 2009
- Lilly CEO Lechleiter Calls for Repair of the 'Engine of Biopharma Innovation'
- Novartis on track to deliver Influenza A (H1N1) vaccine for the US
- Novel agent for treatment of Parkinson's disease - Lu 02-750
- Novo Nordisk increased operating profit by 30% in the first nine months of 2009
- AstraZeneca PLC Third Quarter & Nine Months Results 2009
- Abbott completes acquisition acquisition of privately held eye care company Visiogen